Victory Capital Management Inc. lessened its position in shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by 20.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 532,640 shares of the biotechnology company’s stock after selling 133,800 shares during the quarter. Victory Capital Management Inc. owned 1.90% of Five Prime Therapeutics worth $21,790,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Teachers Advisors LLC boosted its stake in shares of Five Prime Therapeutics by 1.2% in the first quarter. Teachers Advisors LLC now owns 241,371 shares of the biotechnology company’s stock worth $8,726,000 after buying an additional 2,943 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Five Prime Therapeutics by 39.2% in the first quarter. Legal & General Group Plc now owns 9,168 shares of the biotechnology company’s stock worth $331,000 after buying an additional 2,583 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Five Prime Therapeutics by 11.0% in the first quarter. Dimensional Fund Advisors LP now owns 933,410 shares of the biotechnology company’s stock worth $33,743,000 after buying an additional 92,338 shares during the last quarter. Morgan Stanley boosted its stake in shares of Five Prime Therapeutics by 12.7% in the first quarter. Morgan Stanley now owns 121,684 shares of the biotechnology company’s stock worth $4,399,000 after buying an additional 13,750 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Five Prime Therapeutics by 5.8% in the first quarter. Bank of America Corp DE now owns 18,558 shares of the biotechnology company’s stock worth $671,000 after buying an additional 1,025 shares during the last quarter. Institutional investors and hedge funds own 84.08% of the company’s stock.

Five Prime Therapeutics, Inc. (FPRX) opened at $28.83 on Friday. Five Prime Therapeutics, Inc. has a fifty-two week low of $21.41 and a fifty-two week high of $60.98.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.19). The business had revenue of $8.33 million during the quarter, compared to analyst estimates of $16.16 million. Five Prime Therapeutics had a negative return on equity of 41.57% and a negative net margin of 408.42%. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.72) EPS. research analysts anticipate that Five Prime Therapeutics, Inc. will post -5.56 EPS for the current fiscal year.

FPRX has been the topic of a number of recent research reports. Jefferies Group LLC restated a “buy” rating and issued a $52.00 target price on shares of Five Prime Therapeutics in a research note on Tuesday, September 12th. Royal Bank Of Canada upped their target price on Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, November 6th. ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Zacks Investment Research upgraded Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 target price on the stock in a research note on Monday, October 16th. Finally, BMO Capital Markets upgraded Five Prime Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday, October 16th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $64.00.

COPYRIGHT VIOLATION WARNING: “Five Prime Therapeutics, Inc. (FPRX) Shares Sold by Victory Capital Management Inc.” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/12/five-prime-therapeutics-inc-fprx-shares-sold-by-victory-capital-management-inc.html.

In related news, Director William R. Ringo sold 600 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total value of $27,198.00. Following the completion of the transaction, the director now owns 600 shares of the company’s stock, valued at approximately $27,198. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William R. Ringo sold 1,800 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $40.26, for a total value of $72,468.00. Following the completion of the transaction, the director now directly owns 1,200 shares of the company’s stock, valued at approximately $48,312. The disclosure for this sale can be found here. Insiders sold a total of 4,400 shares of company stock valued at $175,666 in the last ninety days. 6.50% of the stock is currently owned by insiders.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics, Inc. (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.